Zhisou powder suppresses airway inflammation in LPS and CS-induced post-infectious cough model mice via TRPA1/TRPV1 channels

• Published in: Journal of ethnopharmacology 2024-04, Vol.324, p.117741-117741, Article 117741
• Main Authors: Xu, Yuan, Cao, Shan, Wang, Shu-fei, Ma, Wei, Gou, Xiao-jun
• Format: Article
• Language: English
• Subjects: Airway inflammation; Animals; Anti-Inflammatory Agents - adverse effects; Cough - chemically induced; Cough - drug therapy; Cough - metabolism; Inflammation - pathology; Lipopolysaccharides - toxicity; Mice; Molecular docking; Molecular Docking Simulation; Neurogenic inflammation; Post-infectious cough; Powders - therapeutic use; TRPA1 Cation Channel - metabolism; TRPA1/TRPV1 channels; TRPV Cation Channels - metabolism; Zhisou powder
• ISSN: 0378-8741; 1872-7573
• DOI: 10.1016/j.jep.2024.117741

Zhisou Powder (ZSP), a traditional Chinese medicine (TCM) prescription, has been widely used in the clinic for the treatment of post-infectious cough (PIC). However, the exact mechanism is not clear. The aim of this study was to investigate the ameliorative effect of ZSP on PIC in mice. The possible mechanisms of action were screened based on network pharmacology, and the potential mechanisms were explored through molecular docking and in vivo experimental validation. Lipopolysaccharide (LPS) (80μg/50 μL) was used to induce PIC in mice, followed by daily exposure to cigarette smoke (CS) for 30 min for 30 d to establish PIC model. The effects of ZSP on PIC mice were observed by detecting the number of coughs and cough latency, peripheral blood and bronchoalveolar lavage fluid (BALF) inflammatory cell counts, enzyme-linked immunosorbent assay (ELISA), and histological analysis. The core targets and key pathways of ZSP on PIC were analyzed using network pharmacology, and TRPA1 and TRPV1 were validated using RT-qPCR and western blotting assays. ZSP effectively reduced the number of coughs and prolonged the cough latency in PIC mice. Airway inflammation was alleviated by reducing the expression levels of the inflammatory mediators TNF-α and IL-1β. ZSP modulated the expression of Substance P, Calcitonin gene-related peptide (CGRP), and nerve growth factor (NGF) in BALF. Based on the results of network pharmacology, the mechanism of action of ZSP may exert anti-neurogenic airway-derived inflammation by regulating the expression of TRPA1 and TRPV1 through the natural active ingredients α-spinastero, shionone and didehydrotuberostemonine. ZSP exerts anti-airway inflammatory effects through inhibition of TRPA1/TRPV1 channels regulating neuropeptides to alleviate cough hypersensitivity and has a favorable therapeutic effect on PIC model mice. It provides theoretical evidence for the clinical application of ZSP. Workflow diagram of the research. [Display omitted] •ZSP has significant potential as a therapeutic intervention for PIC.•ZSP may alleviate post-infectious cough by regulating TRPA1/TRPV1 channels reducing neuropeptides and cytokines in BALF.•ZSP may activate TRPA1/TRPV1 channels via the active ingredients α-spinastero, shionone and didehydrotuberostemonine.